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Chronic pulmonary infections caused by Pseudomonas aeruginosa, Burkholderia cepacia complex and Staphylococcus aureus are
responsible for most of the morbidity and mortality of patients with cystic fibrosis (CF). Little is known about the routes of transmission of
these pathogens from environmental or hospital sources to the patients. We hypothesised that strains of P. aeruginosa, B. cepacia complex
and methicillin-resistant S. aureus (MRSA) are nosocomially acquired by CF patients. Bacterial isolates were obtained from 164 patients
attending the CF Centre of Florence and from the hospital environment and the strains typed using restriction enzymes and pulsed-field gel
electrophoresis (PFGE). Seventy (43%) of patients were colonised by P. aeruginosa, 6 (3.6%) by B. cepacia complex, and 11 (7%) by
MRSA. Three P. aeruginosa strains were isolated from the sinks of the ward. All the MRSA isolates differed from each other. The analysis of
83 P. aeruginosa strains showed identical genotypes in five pairs of patients, whereas from the six patients infected with B. cepacia complex
strains, two patients harboured identical genotypes. These pairs of patients had no contact with each other outside the CF centre and P.
aeruginosa genotypes from the hospital environment differed from these clinical isolates, suggesting a possible common source of infection
within or outside the centre. The study showed that, despite isolation precautions, a minimal risk of cross-infection still existed in the CF
centre and that hygienic standards should be increased to further reduce this risk.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Pulmonary infection; Bacterial isolate
1. Introduction mucociliary clearance [3]. A hallmark of CF is chronic
respiratory infection [4,5] caused mainly by Staphylococ-Cystic fibrosis (CF), is the most common lethal hered-
itary disorder with autosomal recessive heredity in Cauca-
sians with an incidence of clinical disease of
approximately 1 in 2,500 live births [1]. Disease is caused
by mutations in a single gene of chromosome 7, which
encodes the CF Transmembrane Conductance Regulator
(CFTR) [2]. The CFTR protein is a membrane-bound
cAMP-regulated chloride channel, which is thought to
regulate other cell membrane ion channels [3]. In CF
airways, diminished chloride and water secretion affected
by mutated CFTR leads to viscous secretions and impaired1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
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S. aureus isolated from CF patients are methicillin-resistant
(MRSA) [6]. In addition, CF patients may suffer from
infections with Burkholderia cepacia complex, pathogen
which may be associated with fatal necrotising pneumonia
and sepsis (B. cepacia syndrome) [7–11].
P. aeruginosa, a Gram-negative bacterium, is the most
frequently described opportunistic pathogen in CF patients of
all age groups [4,12]. In North America, 81.3% in the age
group of 26–30 years are infected with P. aeruginosa [4].
Similar values are obtained in European countries [12]. It is
ubiquitous and is found in many water reservoirs in the
inanimate and human environment [13]. Similarly,B. cepacia
complex may be found in different environmental sources
[8]. Epidemiological studies using different typing methodsed by Elsevier B.V. All rights reserved.
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transmission of the pathogens to CF patients may occur by
a direct patient-to-patient contact or indirectly via healthy
individuals including the hospital personnel [8,14]. Fur-
thermore, such person-to-person transmission routes may
also be important for MRSA [15]. In addition, transmis-
sion of P. aeruginosa to CF patients may occur via
contaminated environmental reservoirs [13]. However, the
routes by which P. aeruginosa, B. cepacia complex or S.
aureus are acquired inside and outside of hospitals are still
poorly understood. Some CF centers in Europe have
segregated CF patients with and without P. aeruginosa
or B. cepacia complex infection and have stopped CF
summer camps in order to limit cross-infection [16]. Such
measures may also be applied to prevent transmission of
MRSA strains. In addition, various hygienic measures have
been established to decontaminate environmental reservoirs
of P. aeruginosa in hospitals.
Bacterial typing for epidemiological purposes has tradi-
tionally relied on phenotypic characteristics. These methods
are inadequate in conditions in which bacteria undergo
phenotypic conversion such as in the respiratory tract of
CF patients [17]. To circumvent these problems, methods
such as pulsed-field gel electrophoresis (PFGE) [18–22]
have been introduced to type bacterial strains based on
genetic characteristics of microorganisms. Here, we show
that despite isolation precautions, a minimal risk of cross-
infection still exists in our CF centre.2. Materials and methods
Bacterial strains were isolated from respiratory samples
of 164 CF patients (mean age 15.5 years) attending the CF
Regional Centre of Florence, Italy, over the time period of
1998 and 2000. Seventy (43%) patients were colonised by
P. aeruginosa, 6 (3.6%) by B. cepacia complex and 11 (7%)
by MRSA. Chronic P. aeruginosa infection was defined by
the persistent isolation of P. aeruginosa from respiratory
samples for at least 6 consecutive months. Similarly, chronic
pulmonary colonisation by B. cepacia complex, and MRSA
was defined. In 1994, we began to carry out an infection
control policy, based on protocols regarding: segregation,
disinfection, behavioral rules (avoidance of social contacts)
for patients and eradicating treatment for P. aeruginosa first
colonisation (inhaled colistin and oral ciprofloxacin). A
procedure of disinfection was performed everyday on
rooms, furniture, medical equipment and spirometres. Each
room was provided with an outwards direct ventilation
system and after each visit, a further aeration protocol was
performed. Environmental samples, of the most important
pathogens, from rooms (surfaces and sink drain tubes of
three rooms), sinks and spirometers were monthly collected
for bacteriological surveillance. Hand cultures of medical
personnel (three medical doctors and two nurses) were also
performed monthly.Microbiological procedures are based on national and
international guide lines [23]. Bacteria were isolated using
selective agars, were identified using commercial biochem-
ical tests (API 20 NE), including growth on selective agars
and stored at  70jC. Confirmation of the identification of
strains presumed to belong to B. cepacia complex and
genomovars analysis was performed by a reference labora-
tory (Prof. Peter Vandamme, Laboratorium voor Micro-
biologie, Universiteit Gent, Belgium). Bacterial genotypes
were evaluated using PFGE [21]. Briefly, bacterial DNA
was isolated with different procedures for Gram-positive
and Gram-negative bacteria.
2.1. Genotyping of P. aeruginosa and B. cepacia complex
Bacterial strains were grown overnight on brain–heart
agar, inoculated into brain–heart bouillon and grown to an
optical density of 0.3. The suspension incubated with 0.5 M
EDTAwas centrifuged at 5,000 rpm at 4 jC. The pellet was
resuspended in 1 ml of sodium chloride/EDTA (SE) buffer
(15 mM NaCl, 25 mM EDTA, pH 7.4) once heated to 55
jC, 100 Al of a 2% low melting agarose was added and then
the suspension was poured into a plug mold. Sodium
chloride/N-lauryl-sarcosine (SLS) buffer (0.5 M EDTA,
pH 9.51% sodium lauryl-sarcosine + 0.5 mg/ml proteinase
K) was added to the agar plugs and incubated overnight at
55 jC. The agar plugs were washed, cut into 1- to 2-mm
pieces and incubated with the restriction enzyme SpeI (15
U) overnight at 37 jC. A Tris/EDTA buffer, pH 8.0) was
added in order to stop the reaction. A 1% agarose gel was
loaded with the plugs, and the electrophoresis was run at
200 V (6 V/cm) for 24 h and 1- to 25-s intervals.
2.2. Genotyping of S. aureus
The isolates were grown in 5 ml of trypticase soy broth
medium at 37 jC until cultures reached 0.5 absorbance units
(600 nm). One hundred microliters of EDTA were added
and the bacterial culture was cooled to 4 jC. The bacteria
were harvested by centrifugation (12.000 rpm) for 1–2 min
at 4 jC. Isolates were washed in 1 ml of ice-cold buffer (10
ml EDTA, 10 ml EGTA, 1 M NaCl, pH 7.5) and resus-
pended in 100 Al of the same buffer. Bacteria were heated to
55 jC and mixed with 100 Al of 2% low-melting-point
agarose in TE buffer (pH 7.8). The mixture was poured into
slots of a plastic mold and cooled for 20 min at 4 jC.
Agarose plugs were transferred into sterile cups containing 1
ml of lysis buffer (6 mM Tris–HCl, 100 mM EDTA, 1 M
NaCl, 0.5% wt/vol Brij 58, 0.2% wt/vol sodium deoxyco-
late, 0.5% wt/vol lauroyl sarcosine pH 9.0, 500 Ag/ml of
proteinase K). Proteolysis was performed for 24 h at 55 jC
with gentle shaking, with a change of buffer after 12 h. The
agarose plugs were washed five times with 1 ml of TE
buffer (pH 8.0) at 4 jC with gentle shaking. The digestion
was performed by placing a 2-mm slice of each plug in 200
Al of restriction buffer containing 15 U of SmaI. After
Fig. 1. P. aeruginosa strains isolated from 6 out of 13 chronically colonised
patients (1–6) analysed by means of PFGE. Different phenotypes: mucoid
and non-mucoid (lanes a and b, respectively) were isolated from the same
patient.
Fig. 2. B. cepacia strains analysed by means of pulsed field gel
electrophoresis.
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with TE buffer. The plugs were then placed into the slots of
a 1% agarose gel in 0.5 TBE buffer, and the slots were
sealed with 1% agarose. The electrophoresis was run at 200
V (6 V/cm) for 24 h at 12jC with pulse time ranging from 1
to 45 s.
Gels were stained with ethidium bromide and photo-
graphed under UV light. The pattern of restriction fragments
was characteristic for each strain and provided an estimate
of the degree of genomic relationship among the strains. The
relatedness of restriction patterns was analysed by side-to-
side visual comparison using published criteria [22]. Ten-
over criteria were the same for all the tested species. Two
isolates are considered to be closely related if their PFGE
patterns differ in two to three bands, while two isolates are
considered unrelated if their patterns have seven or more
band differences.3. Results
To obtain more information about the situation of cross-
infection between CF patients and infection from environ-Table 1
Identification of bacterial isolates presumed to belong to B. cepacia
complex
Patients Identification and genomovar
1 B. dolosa (formerly gvr IV)
2 B. ubonensis
3 B. ubonensis
4 B. cepacia gvr I
5 B. pyrrocinia (formerly gvr IX)
6 B. multivorans (formerly gvr II)mental sources in our CF centre, we collected strains of P.
aeruginosa, B. cepacia complex and MRSA from CF
patients and the hospital environment and typed the isolates
using PFGE.
Eighty-three P. aeruginosa strains from 64 out of 70
colonised patients (91.4%) were available for genotyping
(19 patients harboured two strains with different phenotype,
mucoid and non-mucoid). In five pairs of patients, identical
genotypes were found. These patients have never been
hospitalised together, suggesting a possible common source
of infection within or outside the centre. All other isolates
differed with regard to the genotype. Interestingly, P. aeru-
ginosa isolated from the same patients (36 strains isolated
from 18 patients), which differed concerning the phenotype
such as mucoid or non-mucoid [24], showed the same
genomic profile (Fig. 1).
Only three environmental samples were positive during
the observation period: three P. aeruginosa strains were
isolated from washbasin sinks. However, they were genet-
ically different from clinical isolates, excluding the possi-
bility of a nosocomial infection route.
Six patients (3.6%) were colonised by strains presumed
to belong to B. cepacia complex. Confirmation of the
identification and genomovar analysis have been performed
(Table 1).
Two strains were found to be identical (Fig. 2; lanes 2
and 3), suggesting cross-infection, while the other four
strains had different genomic profiles (lanes 1, 4–6).Fig. 3. MRSA strains analysed by means of PFGE.
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these two patients did not have any contact outside of the
hospital and these two patients have never been hospitalised
at the same time. Therefore, a possible contamination from a
common source within or outside the hospital occurred.
Eleven patients (7%) suffered from lung infections with
MRSA. PFGE typing showed that all the isolates differed in
their genotypic profile (Fig. 3), suggesting that cross-infec-
tion had not occurred.
All hand cultures of the personnel were negative for P.
aeruginosa, B. cepacia complex and MRSA.4. Discussion
CF patients are predisposed to bacterial colonisation and
infection mostly caused by P. aeruginosa due to the under-
lying disease, although the exact link between the basic
defect which leads to chronic lung infection with these
bacterial pathogens is still unclear. Chronic lung infections
play an important role in the pathogenesis of lung disease
and are associated with a poor prognosis [24]. Thus,
epidemiological monitoring of such infections and the
elucidation of routes of bacterial transmission is vitally
important in CF. Such epidemiological studies concerning
P. aeruginosa show that most CF patients once infected,
harbour only one P. aeruginosa genotype for prolonged
periods of time [25].
Nosocomial acquisition of P. aeruginosa has been de-
scribed previously [26]. Several studies report the spread of
P. aeruginosa within the same clinic [25], and even out-
breaks of multiresistant P. aeruginosa clones in CF clinics
have been reported [27–29]. Identical P. aeruginosa geno-
types were found in five pairs of patients in the present study.
However, P. aeruginosa isolates has been collected in
different times and patients sharing strains were never
hospitalised together. A possible explanation is that patients
may have been colonised by the same source present in the
hospital or in the outside environment [25,30]. Checking
environmental sources of P. aeruginosa in the hospital, we
found no evidence that the inanimate environment was
responsible for strain transmission during the period of the
study. Such transmission routes had been suggested previ-
ously, based on the high contamination rate of washbasin
traps with P. aeruginosa in several hospital settings and the
mechanism of P. aeruginosa—containing aerosols generated
from washbasins [31,14]. We conclude, as supported by
other authors [32], that there is an extremely low risk for
CF patients to acquire P. aeruginosa from other patients. We
can hypothesise a common source or simply an environmen-
tal clone which the patients became infected with. As with P.
aeruginosa, B. cepacia complex may spread both in clinical
settings and during social contacts from person to person
[9,10,33]. The two CF patients harbouring identical B.
cepacia complex genotypes did not have any contact within
or outside of the hospital, suggesting a possible commonsource of infection in or outside the centre. The prevalence of
B. cepacia complex colonisation may vary widely in differ-
ent countries and also in individual centres. These variations
may be due to identification problems, different segregation
policies for colonised patients and outbreaks of epidemic
strains. B. cepacia complex strains isolated from this group
of CF patients were not highly epidemic.
MRSA has become a major nosocomial pathogen with a
progressive increase in prevalence also in CF populations.
MRSA infection in children with CF has an adverse effect
on growth and requires more courses of intravenous anti-
biotics [34]. Investigations about community-acquired S.
aureus in families with and without cystic fibrosis patients
showed that CF patients have a higher susceptibility to this
organism. However, strains transmission was frequent with-
in both CF and non-CF families. A limited number of S.
aureus clones were selected within the community but no
correlation colonisation with these predominant strains and
the disease could be assessed [15]. Other authors did not
find transmission between two family members, indicating a
minimal risk of MRSA acquisition from social contact. On
the other hand, nosocomial transmission was identified,
therefore policies for limiting CF patients admission to
hospital must be supported [35]. Although MRSA coloni-
sation does not seem to negatively affect the clinical status
of the CF patients compared to antibiotic sensitive S. aureus
strains [6], it may pose a major health problem for CF
patients and other patient groups in the future.
In summary, bacterial spreading among patients and
contamination from environmental sources of P. aeruginosa,
B. cepacia complex and MRSA strains do not appear to be a
widespread problem in our centre. Cohort isolation strate-
gies may have helped to reduce cross-colonisation among
patients and to maintain a low prevalence of bacterial
colonisation. Early antibiotic treatment may then have
prevented further infection. The prevalence of P. aeruginosa
colonisation (43%) in our centre is in fact lower than those
reported in literature [4–12]. The pairs of patients infected
with identical genotypes of P. aeruginosa and B. cepacia
complex have never been hospitalised together. This sug-
gests a possible infection with the same clone present in the
hospital or in the outside environment. The importance of
tight infection control measures to prevent bacterial spread-
ing is highlighted.Acknowledgements
The financial support of Telethon-Italy (grant no. E853)
is gratefully acknowledged.References
[1] Lewis PA. The epidemiology of cystic fibrosis. In: HodsonME,Geddes
D, editors. Cystic Fibrosis. London: Chapmen and Hall; 1995.
S. Campana et al. / Journal of Cystic Fibrosis 3 (2004) 159–163 163[2] Santis G. Basic molecular biology. In: Hodson ME, Geddes D, edi-
tors. Cystic Fibrosis. London: Chapman & Hall; 1995.
[3] Sheppard MN. The pathology of cystic fibrosis. In: Hodson ME,
Geddes D, editors. Cystic Fibrosis. London: Chapman and Hall;
1995.
[4] Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Reg-
istry 1997 Annual Data Report. Bethesda, MD, USA: Cystic Fibrosis
Foundation; 1998.
[5] Høiby N. Microbiology of CF. In: Hodson ME, Geddes D, editors.
Cystic Fibrosis. London: Chapman and Hall; 1995.
[6] Thomas SR, Guy KM, Gaya H, Hodson ME. Methicillin-resistant
Staphylococcus aureus: impact at a national cystic fibrosis. J Hosp
Infect 1998;40:203–9.
[7] Tablan OC, Martone WJ, Doershuk CF, et al. Colonisation of the
respiratory tract with Pseudomonas cepacia in cystic fibrosis, Risk
factors and outcomes. Chest 1987;91:527–32.
[8] Do¨ring G, Schaffar L. Epidemiology of pulmonary infection by Pseu-
domonas in patients with cystic fibrosis: a consensus report. Paris:
Association Francaise de Lutte contre la mucoviscidose (AFLM);
1993.
[9] Govan JRWB, Brown PH, Maddison J, et al. Evidence for transmis-
sion of Pseudomonas cepacia by social contact in cystic fibrosis.
Lancet 1993;342:15–9.
[10] Smith DL, Gumery LB, Smith EG, Stableforth DE, Kaufmann ME,
Pitt TL. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis
unit: evidence of person to person transmission. J Clin Microbiol
1993;31:3017–22.
[11] Sun L, Jiang R, Steinbach S, et al. The emergence of a highly trans-
missible lineage of abl + Pseudomonas (Burkholderia) cepacia causing
CF centre epidemics in North America and Britain. Nat Med 1995;
1:661–5.
[12] Stern M, Do¨ring G, Eißing G, et al. Qualita¨tssicherung Mukoviszi-
dose. Zentrum fu¨r Qualita¨tsmanagement im Gesundheitswesen. A¨rz-
tekammer Niedersachsen, Postfach 4749, 30047 Hannover.
[13] Botzenhart K, Do¨ring G. Epidemiology and ecology of Pseudomonas
aeruginosa. In: Campa M, Bandinelli M, Friedman H, editors. Pseu-
domonas aeruginosa as an opportunistic pathogen. New York: Plenum
Publishing; 1993. p. 1–18.
[14] Do¨ring G, Jansen S, Noll H, et al. Distribution and transmission of
Pseudomonas aeruginosa and Burkholderia cepacia in a hospital
ward. Pediatr Pulmonol 1996;21:90–100.
[15] Goerke C, Kraning K, Stern M, Do¨ring G, Botzenhart K, Wolz C.
Molecular epidemiology of community-acquired Staphylococcus au-
reus in families with and without cystic fibrosis patients. J Infect Dis
2000;181:984–9.
[16] Høiby N, Koch C. Pseudomonas aeruginosa infection in cystic fibro-
sis and its management. Thorax 1990;45:881–4.
[17] Ojeniyi B, Stenn Pedersen U, Høiby N. Comparison of genome fin-
gerprinting with conventional typing methods used on Pseudomonas
aeruginosa isolates from cystic fibrosis patients. APMIS 1993;101:
168–75.
[18] Grundmann H, Schneider C, Hartung D, Daschner FD, Pitt TL. Dis-
criminatory power of three DNA-based typing techniques for Pseu-
domonas aeruginosa. J Clin Microbiol 1995;33:528–34.
[19] Ichiyama S, Ohta M, Shimokata K, Kato N, Takeuchi J. Genomic
fingerprinting by pulsed-field gel electrophoresis as an epidemiolog-ical marker for study of nosocomial infections caused by methicillin-
resistant Staphylococcus aureus. J Clin Microbiol 1991;29:2690–5.
[20] Anderson DJ, Kuhns JS, Vasil ML, Gerding DN, Janoff EN. DNA
fingerprinting by pulsed field gel electrophoresis and rybotyping to
distinguish Pseudomonas cepacia isolates from a nosocomial out-
break. J Clin Microbiol 1991;29:648–9.
[21] Grothues D, Koopmann U, von der Hardt H, Tu¨mmler B. Genome
fingerprinting of Pseudomonas aeruginosa indicates colonization of
cystic fibrosis siblings with closely related strains. J Clin Microbiol
1988;26:1973–7.
[22] Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal
DNA restriction patterns produced by pulsed field gel electrophoresis:
criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233–9.
[23] Saiman L, Siegel J, and the Cystic Fibrosis Foundation Consesus
Conference of Infection Control Participants. Am J Infect Control
2003;31(3 Suppl):S1–S62.
[24] Do¨ring G, Conway SP, Heijerman HGM, et al. for the Consensus
Committee. Antibiotic therapy against Pseudomonas aeruginosa in
cystic fibrosis: a European consensus. Eur Respir J 2000;16:749–67.
[25] Tu¨mmler B, Koopmann U, Grothues D, Weissbrodt H, Steinkamp G,
Vonderhardt H. Nosocomial acquisition of Pseudomonas aeruginosa
by cystic fibrosis patients. J Clin Microbiol 1991;29:1265–7.
[26] MacCallum SJ, Corkill J, Gallagher M, Ledson MJ, Hart CA, Wal-
shaw MJ. Superinfection with a transmissible strain of Pseudomonas
aeruginosa in adults with cystic fibrosis chronically colonized by
Pseudomonas aeruginosa. Lancet 2001;358:558–60.
[27] Jones AM, Govan JRW, Doherty CJ, et al. Spread of a multiresistant
strain of Pseudomonas aeruginosa in a adult cystic fibrosis clinic.
Lancet 2001;358:557–8.
[28] Pedersen SS, Koch C, Høiby N, Rosendal K. An epidemic spread of
multiresistant Pseudomonas aeruginosa in a cystic fibrosis center.
J Antimicrob Chemother 1986;17:505–16.
[29] Armstrong DS, Carzino R, Carlin J, Nixon G, Grimwood K. Long-
term outbreak of a transmissible virulent strain of Pseudomonas aer-
uginosa in a paediatric cystic fibrosis clinic. Pediatr Pulmonol, Suppl
2000;20:285.
[30] Wolz C, Kiosz G, Ogle JW, et al. Pseudomonas aeruginosa cross-
colonization and persistence in patients with cystic fibrosis: Use of a
DNA probe. Epidemiol Infect 1989;102:205–14.
[31] Do¨ring G, Ulrich M, Mu¨ller W, et al. Generation of Pseudomonas
aeruginosa aerosols during handwashing from contaminated sink
drains, transmission to hands of hospital personnel, and its prevention
by use of a new heating device. Z Hyg 1991;191:494–505.
[32] Speert DP, Campbell ME, Henry DA, et al. Epidemiology of Pseu-
domonas aeruginosa in cystic fibrosis in British Columbia, Canada.
Am J Respir Crit Care Med 2002;166:988–93.
[33] Mahenthiralingam E, Campbell ME, Henry DA, Speert DP. Epidemi-
ology of Burkholderia cepacia infection in patient with cystic fibrosis:
analysis by randomly amplified polymorphic DNA fingerprinting.
J Clin Microbiol 1996;34:2914–20.
[34] Miall LS, McGinley NT, Brownlee KG, Conway SP. Methicillin re-
sistant Staphylococcus aureus (MRSA) infection in cystic fibrosis.
Arch Dis Child 2001;84:160–2.
[35] Givney R, Vickery A, Holliday A, Pegler M, Benn R. Methicillin-
resistant Staphylococcus aureus in a cystic fibrosis unit. J Hosp Infect
1997;35:27–36.
